0001479290-24-000104.txt : 20240702 0001479290-24-000104.hdr.sgml : 20240702 20240702174739 ACCESSION NUMBER: 0001479290-24-000104 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240630 FILED AS OF DATE: 20240702 DATE AS OF CHANGE: 20240702 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Foley Mark J CENTRAL INDEX KEY: 0001529196 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 241097364 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 wk-form4_1719956853.xml FORM 4 X0508 4 2024-06-30 0 0001479290 Revance Therapeutics, Inc. RVNC 0001529196 Foley Mark J C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, 20TH FLOOR NASHVILLE TN 37203 1 1 0 0 CEO 0 Common Stock 2024-06-30 5 A 0 E 1000 2.1845 A 995935 D Common Stock 110913 I See footnote These shares were acquired by Mr. Foley under the Issuer's 2014 Employee Stock Purchase Plan on June 30,2024 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. /s/ Dwight Moxie, Attorney-in-Fact 2024-07-02